by MM360 Staff | Jul 25, 2025 | Publications
Rofo. 2025 Jul 23. doi: 10.1055/a-2625-5643. Online ahead of print. ABSTRACT Multiple myeloma (MM) is the second most common hemato-oncological malignancy, characterized by the clonal proliferation of malignant plasma cells and bone marrow infiltration. The degree of...
by MM360 Staff | Jul 24, 2025 | Myeloma News
Source: Pharmacy Times articles Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma. Read More
by Victoria Langowska | Jul 23, 2025 | Uncategorized
CHICAGO — In this video, Sham Mailankody, MBBS, highlights data from a study of carfilzomib, lenalidomide and dexamethasone, with or without daratumumab, for patients with newly diagnosed multiple myeloma.“Four drugs appear to be better than three drugs, even in the...
by Victoria Langowska | Jul 23, 2025 | Uncategorized
CHICAGO — In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 patients receiving ciltacabtagene autoleucel, or cilta-cel, for the treatment of relapsed or refractory multiple myeloma.“A third of the patients were...
by MM360 Staff | Jul 22, 2025 | Publications
J Geriatr Oncol. 2025 Jul 19;16(7):102321. doi: 10.1016/j.jgo.2025.102321. Online ahead of print. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is an incurable blood cancer with improved survival rates due to advances in treatment, including stem cell transplantation,...
